Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Plus Pembrolizumab in Advanced Urothelial Carcinoma
NCT04856189Phase 2Terminated
- Start
- Apr 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in urothelial carcinoma (UC). Started Apr 2021; status: terminated.
02
Drugs
selinexor
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04856189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856189.